Remnant Duct Dilatation Rarely Signals IPMN Recurrence : Ann Surg | Jun 2026

Introduction:

Patients undergoing pancreatoduodenectomy for non invasive intraductal papillary mucinous neoplasm (IPMN) require long-term surveillance because of the risk of disease recurrence in the pancreatic remnant. New pancreatic duct (PD) dilatation is commonly detected during follow-up imaging, but its clinical significance remains uncertain, often creating a dilemma regarding further investigation or completion pancreatectomy.

Problem Statement:

Although main pancreatic duct dilatation is a recognized radiological hallmark of IPMN, postoperative duct dilatation may also result from benign causes such as anastomotic changes, aging, pancreatitis, or physiological postoperative remodeling. Distinguishing benign ductal dilatation from true IPMN recurrence is essential to avoid unnecessary surgery while ensuring timely detection of invasive disease.

Summary:

This international multicenter study evaluated the natural history of remnant pancreatic duct dilatation following pancreatoduodenectomy for non invasive IPMN. During long-term surveillance, more than one-quarter of patients developed new pancreatic duct dilatation, making it a frequent postoperative finding. Older age and longer duration of follow-up were the only factors associated with duct enlargement, whereas the original IPMN subtype and preoperative duct diameter did not predict its development. Importantly, although duct dilatation frequently raised suspicion for recurrent IPMN, progression to invasive pancreatic cancer was exceptionally uncommon. Only a very small proportion of patients ultimately required completion pancreatectomy for invasive carcinoma, and most of these patients had high-grade dysplasia in the original surgical specimen, suggesting that initial pathological severity may be more informative than postoperative duct dilatation alone. The findings indicate that remnant pancreatic duct dilatation is often a physiological consequence of long-term postoperative changes rather than evidence of recurrent neoplasia. Clinically, these results support a cautious, surveillance-based approach rather than immediate surgical intervention when isolated duct dilatation is identified after pancreatoduodenectomy. Overall, the study provides reassuring evidence that new remnant duct dilatation is common but rarely represents clinically significant IPMN recurrence, helping refine postoperative surveillance strategies and reducing the risk of unnecessary completion pancreatectomy.